These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in the press release issued earlier today. Today, we reported organic sales growth of 7.5% excluding COVID test sales. Recently launched new products generated nearly half a billion dollars in sales this quarter and added more than 100 basis points to organic sales growth.
Strong brand recognition, combined with favorable demographic and dietary trends, including an increased focus on protein intake and immune system health, continues to fuel our growth. Growth in adult nutrition was driven by 10% growth in international markets, where we continue to see strong demand for both Ensure and Glucerna. To support future growth, we continue to invest in these well-known brands to ensure they evolve along with changing consumer preferences. Moving to diagnostics, we saw modest sales growth in the quarter excluding COVID testing sales.
Excluding China, core lab diagnostics grew 7%, with markets such as the U.S. showing an acceleration in growth in the third quarter compared to the growth in the first half of this year. Our strong, consistent performance outside of China reflects durable underlying demand in markets around the world. Turning to EPD, sales increased 7%, led by double-digit growth in our key 15 markets, highlighting broad-based demand and strong commercial execution.
| Metric | Period | Current guidance |
|---|---|---|
| Organic sales growth | Full year 2025 | High single-digit (Reaffirmed) |
| EPS growth | Full year 2025 | Double-digit (Reaffirmed) |
| Foreign exchange impact on reported sales | Q4 2025 | Approximately 1.5% favorable (New) |
| U.S. diabetes care growth | Full year 2025 | Over 20% (On track with original assumption) |
| Metric | YoY | Note |
|---|---|---|
| Nutrition | +4% | Led by adult nutrition with 10% international growth in Ensure and Glucerna; partly offset by U.S. pediatric share losses. |
| Diagnostics (ex-COVID) | Modest growth | China price and volume pressure from VBP and DRG changes; core lab diagnostics grew 7% excluding China. |
| Point-of-care diagnostics | +8% | Growing adoption of the point-of-care concussion test and high-sensitivity troponin test. |
| Established Pharmaceuticals (EPD) | +7% | Double-digit growth in key 15 markets across gastroenterology, cardiometabolic, and pain management; biosimilar progress. |
| Medical devices | +12.5% | Double-digit growth across diabetes care, electrophysiology, cardiac rhythm management, heart failure, and structural heart. |
| Diabetes care (CGM) | +17% | Strong demand for FreeStyle Libre; CGM sales of $2 billion in the quarter. |
| Structural heart | +11% | Share gains in TAVR and growing adoption of Triclip, plus regulatory milestones in Japan and Europe. |
| Cardiac rhythm management | +13% | Strong uptake of the Aveir leadless pacemaker, outperforming the market for 10 consecutive quarters. |
| Heart failure | +12% | Growth across ventricular assist devices and CardioMEMS. |
| Vascular | +5% | Strong vessel closure products and increasing contributions from the ESPRI below-the-knee resorbable stent. |
| Neuromodulation | +7% | Strong international performance of the Eterna rechargeable spinal cord stimulation device. |
| U.S. diagnostics | +10% | New business capture and share gains from a competitive portfolio. |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| China diagnostics VBP headwind | Discussed in July as over $1 billion headwind | Q3 decline in line with Q1 and Q2; volume beginning to recover, headwind expected to lap starting Q4 | Declining |
| Electrophysiology and Volt PFA catheter | — | Strong European rollout with positive physician feedback; U.S. launch planned for next year | Rising |
| Cardiac rhythm management / Aveir leadless pacemaker | — | Now the fastest growing medtech line at 13%; single chamber ~50% penetrated, dual chamber sub-10% | Rising |
| Diabetes CGM basal segment penetration | — | U.S. basal only ~20% penetrated, international under 5%; dual analyte sensor and potential CMS type 2 non-insulin coverage as drivers | Rising |
| Tariff impact and gross margin mitigation | — | First meaningful tariff impact hit gross margin in Q3; dedicated mitigation teams targeting continued expansion toward ~57% profile | Steady |
| 2026 outlook confidence | Comfortable with consensus expressed in July | Reaffirmed comfort with ~7.5% sales and 10% EPS growth consensus for 2026 | Steady |